Prescription Drug Policy: The Year In Review, And The Year Ahead
From the article:
This past year was once again filled with health policy news. Unlike 2017's congressional efforts to repeal the Affordable Care Act (ACA), 2018's news focused more on executive actions around health care as well as the politics of the issue, both leading up to and in the wake of the November elections.
Through it all, prescription drug policy issues have remained front and center, with a strong -- though not complete -- focus on the question of prescription drug pricing. In this post, I review five key developments from the past year (and revisit my predictions from last year's post!) and offer five things to watch for in 2019.bioethics pharmaceuticals rachel sachs regulation research